Mutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2211-2220

  Bowlin, Nicholas O ^a   Williams, John D ^a   Knoten, Claire A ^b   Torhan, Matthew C ^a   Tashjian, Tommy F ^a   Li, Bing ^a   Aiello, Daniel ^a   Mecsas, Joan ^c   Hauser, Alan R ^b   Peet, Norton P ^a   Bowlin, Terry L ^a   Moir, Donald T ^a  

^a MICROBIOTIX INC   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL PROTEIN; CHAPERONE; GENTAMICIN; MBX 2359; PSEUDOMONAS AEUROGINOSA NEEDLE PROTEIN; SPECTINOMYCIN; UNCLASSIFIED DRUG;

ALLELE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CODON; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENETIC CODE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEQUENCE ANALYSIS; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; TYPE III SECRETION SYSTEM; WILD TYPE;

CARRIER PROTEINS; IMMUNOBLOTTING; MUTATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRULENCE;

EID: 84896983589     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02795-13     Document Type: Article

References (45)

1. Hauser AR. 2009. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat. Rev. Microbiol. 7:654-665. http://dx.doi.org/10. 1038/nrmicro2199.
2. Izore T, Job V, Dessen A. 2011. Biogenesis, regulation, and targeting of the type III secretion system. Structure 19:603-612. http://dx.doi.org/10.1016/ j.str.2011.03.015.
3. Engel J, Balachandran P. 2009. Role of Pseudomonas aeruginosa type III effectors in disease. Curr. Opin. Microbiol. 12:61-66. http://dx.doi.org/10. 1016/j.mib.2008.12.007.
4. Coburn B, Sekirov I, Finlay BB. 2007. Type III secretion systems and disease. Clin. Microbiol. Rev. 20:535-549. http://dx.doi.org/10.1128/CMR.00013- 07. (Pubitemid 47623767)
5. Shaver CM, Hauser AR. 2004. Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect. Immun. 72:6969-6977. http://dx.doi.org/10.1128/IAI.72.12.6969-6977.2004. (Pubitemid 39552365)
6. Smith RS, Wolfgang MC, Lory S. 2004. An adenylate cyclase-controlled signaling network regulates Pseudomonas aeruginosa virulence in a mouse model of acute pneumonia. Infect. Immun. 72:1677-1684. http://dx.doi.org/10.1128/IAI.72. 3.1677-1684.2004. (Pubitemid 38263791)
7. El Solh AA, Akinnusi ME, Wiener-Kronish JP, Lynch SV, Pineda LA, Szarpa K. 2008. Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 178:513-519. http://dx.doi.org/10.1164/rccm.200802-239OC.
8. El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H. 2012. Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit. Care Med. 40:1157-1163. http://dx.doi.org/10.1097/CCM.0b013e3182377906.
9. Hauser AR, Cobb E, Bodi M, Mariscal D, Valles J, Engel JN, Rello J. 2002. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit. Care Med. 30:521-528. http://dx.doi.org/10.1097/00003246-200203000-00005. (Pubitemid 34214611)
10. Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, Fujimoto J, Sawa T, Frank DW, Wiener-Kronish JP. 2001. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J. Infect. Dis. 183:1767-1774. http://dx.doi.org/10.1086/320737. (Pubitemid 32523239)
11. Zhuo H, Yang K, Lynch SV, Dotson RH, Glidden DV, Singh G, Webb WR, Elicker BM, Garcia O, Brown R, Sawa Y, Misset B, Wiener-Kronish JP. 2008. Increased mortality of ventilated patients with endotracheal Pseudomonas aeruginosa without clinical signs of infection. Crit. Care Med. 36:2495-2503. http://dx.doi.org/10.1097/CCM.0b013e318183f3f8.
12. Negrea A, Bjur E, Ygberg SE, Elofsson M, Wolf-Watz H, Rhen M. 2007. Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar Typhimurium. Antimicrob. Agents Chemother. 51:2867-2876. http://dx.doi.org/10.1128/AAC.00223-07. (Pubitemid 47206224)
13. Kauppi AM, Nordfelth R, Uvell H, Wolf-Watz H, Elofsson M. 2003. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem. Biol. 10:241-249. http://dx.doi.org/10.1016/S1074-5521(03)00046-2. (Pubitemid 36380281)
14. Harmon DE, Davis AJ, Castillo C, Mecsas J. 2010. Identification and characterization of small-molecule inhibitors of Yop translocation in Yersinia pseudotuberculosis. Antimicrob. Agents Chemother. 54:3241-3254. http://dx.doi.org/10.1128/AAC.00364-10.
15. Aiello D, Williams JD, Majgier-Baranowska H, Patel I, Peet NP, Huang J, Lory S, Bowlin TL, Moir DT. 2010. Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion. Antimicrob. Agents Chemother. 54:1988-1999. http://dx.doi.org/10.1128/AAC.01598-09.
16. Grier MC, Garrity-Ryan LK, Bartlett VJ, Klausner KA, Donovan PJ, Dudley C, Alekshun MN, Tanaka SK, Draper MP, Levy SB, Kim OK. 2010. N-hydroxybenzimidazole inhibitors of ExsA MAR transcription factor in Pseudomonas aeruginosa: in vitro anti-virulence activity and metabolic stability. Bioorg. Med. Chem. Lett. 20:3380-3383. http://dx.doi.org/10.1016/j. bmcl.2010.04.014.
17. Baer M, Sawa T, Flynn P, Luehrsen K, Martinez D, Wiener-Kronish JP, Yarranton G, Bebbington C. 2009. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect. Immun. 77:1083-1090. http://dx.doi.org/10.1128/IAI.00815-08.
18. Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, Sawa T. 2002. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J. Infect. Dis. 186:64-73. http://dx.doi.org/10.1086/341069. (Pubitemid 34666915)
19. Francois B, Luyt CE, Dugard A, Wolff M, Diehl JL, Jaber S, Forel JM, Garot D, Kipnis E, Mebazaa A, Misset B, Andremont A, Ploy MC, Jacobs A, Yarranton G, Pearce T, Fagon JY, Chastre J. 2012. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit. Care Med. 40:2320-2326. http://dx.doi.org/10. 1097/CCM.0b013e31825334f6.
20. Milla CE, Chmiel JF, Accurso FJ, Vandevanter DR, Konstan MW, Yarranton G, Geller DE, KB001 Study Group. 2013. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr. Pulmonol. doi:http://dx.doi.org/10.1002/ppul.22890.
21. Sato H, Hunt ML, Weiner JJ, Hansen AT, Frank DW. 2011. Modified needle-tip PcrV proteins reveal distinct phenotypes relevant to the control of type III secretion and intoxication by Pseudomonas aeruginosa. PLoS One 6:e18356. http://dx.doi.org/10.1371/journal.pone.0018356.
22. Holloway BW, Krishnapillai V, Morgan AF. 1979. Chromosomal genetics of Pseudomonas. Microbiol. Rev. 43:73-102. (Pubitemid 9169387)
23. Bradley DE. 1974. The adsorption of Pseudomonas aeruginosa pilus-dependent bacteriophages to a host mutant with nonretractile pili. Virology 58:149-163. http://dx.doi.org/10.1016/0042-6822(74)90150-0.
24. de Lorenzo V, Timmis KN. 1994. Analysis and construction of stable phenotypes in gram-negative bacteria with Tn5- and Tn10-derived mini-transposons. Methods Enzymol. 235:386-405. http://dx.doi.org/10.1016/0076- 6879(94)35157-0. (Pubitemid 24191454)
25. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV. 2000. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406:959-964. http://dx.doi.org/10.1038/35023079.
26. Chuanchuen R, Murata T, Gotoh N, Schweizer HP. 2005. Substrate-dependent utilization of OprM orOpmHby the Pseudomonas aeruginosa MexJK efflux pump. Antimicrob. Agents Chemother. 49:2133-2136. http://dx.doi.org/10.1128/AAC.49.5. 2133-2136.2005. (Pubitemid 40631640)
27. Moir DT, Di M, Moore RA, Schweizer HP, Woods DE. 2008. Cellular reporter screens for inhibitors of Burkholderia pseudomallei targets in Pseudomonas aeruginosa. Trans. R. Soc. Trop. Med. Hyg. 102(Suppl 1):S152-S162. http://dx.doi.org/10.1016/S0035-9203(08)70033-6.
28. Hoang TT, Kutchma AJ, Becher A, Schweizer HP. 2000. Integrationproficient plasmids for Pseudomonas aeruginosa: site-specific integration and use for engineering of reporter and expression strains. Plasmid 43:59-72. http://dx.doi.org/10.1006/plas.1999.1441. (Pubitemid 30049004)
29. Diaz MH, Hauser AR. 2010. Pseudomonas aeruginosa cytotoxin ExoU is injected into phagocytic cells during acute pneumonia. Infect. Immun. 78:1447-1456. http://dx.doi.org/10.1128/IAI.01134-09.
30. Roehl RA, Phibbs PV, Jr. 1982. Characterization and genetic mapping of fructose phosphotransferase mutations in Pseudomonas aeruginosa. J. Bacteriol. 149:897-905. (Pubitemid 12101307)
31. Wolfgang MC, Lee VT, Gilmore ME, Lory S. 2003. Coordinate regulation of bacterial virulence genes by a novel adenylate cyclase-dependent signaling pathway. Dev. Cell 4:253-263. http://dx.doi.org/10.1016/S1534-5807(03)00019-4. (Pubitemid 36221801)
32. Moir DT, Di M, Opperman T, Schweizer HP, Bowlin TL. 2007. A high-throughput, homogeneous, bioluminescent assay for Pseudomonas aeruginosa gyrase inhibitors and other DNA-damaging agents. J. Biomol. Screen. 12:855-864. http://dx.doi.org/10.1177/1087057107304729. (Pubitemid 47340706)
33. Choi KH, Kumar A, Schweizer HP. 2006. A 10-min method for preparation of highly electrocompetent Pseudomonas aeruginosa cells: application for DNA fragment transfer between chromosomes and plasmid transformation. J. Microbiol. Methods 64:391-397. http://dx.doi.org/10.1016/j.mimet.2005.06.001. (Pubitemid 43212814)
34. Hauser AR, Kang PJ, Engel JN. 1998. PepA, a secreted protein of Pseudomonas aeruginosa, is necessary for cytotoxicity and virulence. Mol. Microbiol. 27:807-818. http://dx.doi.org/10.1046/j.1365-2958.1998.00727.x. (Pubitemid 28081989)
35. Nordfelth R, Kauppi AM, Norberg HA, Wolf-Watz H, Elofsson M. 2005. Small-molecule inhibitors specifically targeting type III secretion. Infect. Immun. 73:3104-3114. http://dx.doi.org/10.1128/IAI.73.5.3104-3114.2005. (Pubitemid 40570380)
36. Loquet A, Sgourakis NG, Gupta R, Giller K, Riedel D, Goosmann C, Griesinger C, Kolbe M, Baker D, Becker S, Lange A. 2012. Atomic model of the type III secretion system needle. Nature 486:276-279. http://dx.doi.org/10.1038/ nature11079.
37. Rietsch A, Vallet-Gely I, Dove SL, Mekalanos JJ. 2005. ExsE, a secreted regulator of type III secretion genes in Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 102:8006-8011. http://dx.doi.org/10.1073/pnas.0503005102. (Pubitemid 40781053)
38. Urbanowski ML, Lykken GL, Yahr TL. 2005. A secreted regulatory protein couples transcription to the secretory activity of the Pseudomonas aeruginosa type III secretion system. Proc. Natl. Acad. Sci. U. S. A. 102:9930-9935. http://dx.doi.org/10.1073/pnas.0504405102. (Pubitemid 40993670)
39. Quinaud M, Chabert J, Faudry E, Neumann E, Lemaire D, Pastor A, Elsen S, Dessen A, Attree I. 2005. The PscE-PscF-PscG complex controls type III secretion needle biogenesis in Pseudomonas aeruginosa. J. Biol. Chem. 280:36293-36300. http://dx.doi.org/10.1074/jbc.M508089200. (Pubitemid 41633902)
40. Zlokarnik G, Negulescu PA, Knapp TE, Mere L, Burres N, Feng L, Whitney M, Roemer K, Tsien RY. 1998. Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. Science 279:84-88. http://dx.doi.org/10.1126/science.279.5347.84. (Pubitemid 28079160)
41. Quinaud M, Ple S, Job V, Contreras-Martel C, Simorre JP, Attree I, Dessen A. 2007. Structure of the heterotrimeric complex that regulates type III secretion needle formation. Proc. Natl. Acad. Sci. U. S. A. 104:7803-7808. http://dx.doi.org/10.1073/pnas.0610098104. (Pubitemid 47185832)
42. Sun P, Tropea JE, Austin BP, Cherry S, Waugh DS. 2008. Structural characterization of the Yersinia pestis type III secretion system needle protein YscF in complex with its heterodimeric chaperone YscE/YscG. J. Mol. Biol. 377:819-830. http://dx.doi.org/10.1016/j.jmb.2007.12.067.
43. Deane JE, Roversi P, Cordes FS, Johnson S, Kenjale R, Daniell S, Booy F, Picking WD, Picking WL, Blocker AJ, Lea SM. 2006. Molecular model of a type III secretion system needle: implications for host-cell sensing. Proc. Natl. Acad. Sci. U. S. A. 103:12529-12533. http://dx.doi.org/10.1073/pnas.0602689103. (Pubitemid 44267292)
44. Demers JP, Sgourakis NG, Gupta R, Loquet A, Giller K, Riedel D, Laube B, Kolbe M, Baker D, Becker S, Lange A. 2013. The common structural architecture of Shigella flexneri and Salmonella typhimurium type three secretion needles. PLoS Pathog. 9:e1003245. http://dx.doi.org/10.1371/journal.ppat.1003245.
45. Fujii T, Cheung M, Blanco A, Kato T, Blocker AJ, Namba K. 2012. Structure of a type III secretion needle at 7-A resolution provides insights into its assembly and signaling mechanisms. Proc. Natl. Acad. Sci. U. S. A. 109:4461-4466. http://dx.doi.org/10.1073/pnas.1116126109.